Sorry about your friend but we all have lost people. Now onto actual motives; If you really believe in this therapy why aren’t you screaming from the rooftop to get this in the hands of a company with proper governance and resources? Why aren’t you outraged there’s been no pediatric trial since L has no side effects? Why would you threaten skeptics who are trying to change things for the better by insisting on transparency?

We’re talking about an American company and an American institution so why on earth do you feel the need to bring up the UK legal system?

More dump graphics. You don’t even know the current state of affairs between UCLA and NWBO never mind the nitty gritty of the contract itself, old new or otherwise.

The outcome may be the same but the process was tweaked so NWBO could call it their own. Why is this so hard? Tell you what, write LP to please put a clear explanation up on their website so we can all finally call it a day on this topic.

LOL. ALT-DC is at once both UCLA’s original version and NWBO’s DCVAX depending on the study and name usage permission.

You keep forgetting that there is an article out there where in print Dr. Liau says that NWBO took her formula and tweaked it to call it their own.

Yeah…”Inquiries”. 🤷‍♀️. There was also a study group that ran alongside the trial that we’ve never heard about.🤷‍♀️. Seems to be no clear record with UCLA treatments either. It’s a mess.

No data on it but judging by social media and LP’s silence, it was very few. And those few who did, it appears the revenue went to Advent and those books are not available to scrutinize. 🤷‍♀️🐑

No take here on how many attended the ASM in person?

Patient population in this trial and with actual GBM? You know the answer.

It’s a shame shareholders have to rely on some anonymous poster’s ASM transcript.

Noticed nobody mentioned “Dr. Monica Bosch, our Chief Technical Officer” who was on the call. Is she related?

This her?

https://www.researchgate.net/profile/Monica-Bosch-Morato

Yeah, because what’s to worry about with a broke One women show biotech, who’s addicted to consultants and already burned nearly two billion shares with no ROI in sight, and just one old lousy trial under their belt?

>>No, I believe she went with fear mongering looneys this year.

Speaking of which, she didn’t mention the “Thundering herd” this year? They must taken a wrong turn.

Because skeptics like being right?

>>Why do this on a whortless company?

Research cash is everything to biotech and to regulators. They both benefit greatly from it. If you feel confident enough to post here you should’ve figured that out by now.🤷🏻‍♂️

>>The best is the comment that MHRA gave a last chance to raise more money before it ends.

DCVAX’s trial was first to sign on with MHRA’s program. They made a big deal about it back then, so the UK regulator doesn’t want to advertise it bombed or worse. Notice you don’t see the various charities pushing for L anymore. They’ve likely been told to stop inquiring, imo.

Remember, I was the one who first posted that meeting video here suggesting it was with CHM. Whether it be CHM or MHRA, they are both helping NWBO kick the can down the road, imo. The lack of a pediatric trial is the giveaway that this is going nowhere for now, imo.

I think you and Seeking are both wrong on this. LP’s not lying when she says she has a special relationship with MHRA going back more than ten years. They’re providing cover by keeping everything vague with no paper trail. Just passing the MAA around like a hot potato.

Like I said a long time ago, MHRA has its own reasons for dragging this out. Perhaps they’re giving NWBO an opportunity to raise more cash for research and a confirmatory? Perhaps they first want to see trial results of another more affordable therapy? Perhaps they’re waiting for more research on exactly why it works on some and not others? Or perhaps MHRA knows NICE will never pay for it so the government doesn’t want bad press or lawyer badgering / patient lawsuits? These are the only things that make sense at this point, imo. LP knows but she’s not telling, IMO, and MHRA is providing cover for whatever reason.

You forgot the PR on the notoriously stingy UK paying for it. 🤷🏻‍♂️

Dilution or not, the market cap is the market cap, either it’s pricey or not. I do agree, however, that sneaky dilution is a great method for retail rug pulling. Which we’ve seen over and over again with this one. But my point is the final rug pull should’ve happened already. So either there is no final MHRA decision yet or somehow Advent is worth $300M.

No idea how you got from my post to what you just spewed? 11 years later! You’re crazy if you think the one women non scientist who never shows her face, orchestrated all that. No way. They’re gearing up for mRNA and whatever else.

Forget the stock price, I thought we both agreed the market cap was quite pricey here? That’s my point, it’s too stable to be holding that kind of news for a month, imo.

And shame on Bigger for calling that crap a “Good presentation by LP”. Then in the next post he’s applauding another biotech’s director for a million dollar open market purchase. Shame on you!

Appeal or not, no way a flat out rejection a month ago without a bunch of investors catching wind, IMO. My guess is it’s a nebulous “let’s wait and see” situation.

I hear you but would be surprised the stock wouldn’t have nosedived by now.

Either way, I just can’t believe that kind of material information could be kept secret for so long? What might make sense is CHM maybe recommending waiting for other study data on both L and other therapies?

Yes, there are other GBM trials being reviewed by CHM but only one has submitted an application, so far as I know. That being L.

>>The Commission considered and advised on an application for a marketing authorisation for
a medicinal product used to treat glioblastoma (a cancer of the brain).

All UK eyes are on this trial.

Emerging Trials: The UK has launched the 5G Trial (Next-Generation Agile Genomically Guided Glioma), a major adaptive clinical trial that uses real-time whole-genome sequencing to match patients with targeted drug combinations.

She has to know. She’s fibbing like a politician, IMO.

She can’t possibly not know what’s going on with the app. Impossible.

Very curious to see how LG’s blocker goes and the effect his trust’s unloading has on the stock, assuming they do sell around here?

Looks like Disciples are waiting for the smoke to clear so they can resume pumping.

She even denied her poor shareholders a ASM replay or transcript. They had to rely on AI Slave for it instead. 🤷‍♀️🤦‍♀️

Relax. 😂🐑

“So no to the fear mongers. We are not going to just burn through a whole bunch of shares at a crazy, fast pace.”

The elephant in the room is NICE reimbursement which you and LP breezed right over.

Why does she appear to work so hard to lose shareholders while the pump crews try so hard to maintain them, that is a real question?

Looking forward to the 2030 readout. 🙄🤷‍♀️

I think someone messed up on those units using the metric system instead of the imperial system? 😂🚀

First she’ll explain how they were able to replicate part number 3844828-4475 saving shareholders $100,000. 🤷‍♀️